Literature DB >> 12695752

Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma.

Sandra Doyle1, Paul O'Brien, Karen Murphy, Chrissann Fleming, James O'Donnell.   

Abstract

Solvent/detergent (S/D) plasma is being increasingly widely used in clinical practice, as it carries significantly lower risk of lipid-enveloped viral transmission than standard fresh frozen plasma (FFP). However, previous reports have suggested that S/D processing might influence the coagulation factor content of plasma. We have investigated this question by measuring procoagulant factors (fibrinogen, factor V and factor VIII), anticoagulant factors (protein C and protein S) and routine coagulation screening tests (prothrombin time and activated partial thromboplastin time) in 48 single-donor units of FFP, and in 16 units of S/D plasma (Octaplas). All routine coagulation screening tests, factor VII and protein C levels were within the normal reference range for both S/D plasma and FFP. However, we found significant reductions in factor V (31%), factor VIII (28%) and protein S (50%) in S/D plasma. The observed quantitative differences in coagulation factor levels may be further exacerbated by the lower volume of solvent detergent plasma units (200 ml) compared with units of standard fresh frozen plasma (250 ml). These findings are of potential clinical significance, particularly in those patients with liver disease, constitutional factor V deficiency and congenital or acquired protein S deficiency.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695752     DOI: 10.1097/01.mbc.0000061298.28953.7d

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  8 in total

Review 1.  Recommendations for the transfusion of plasma and platelets.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

2.  Plasma, guidelines, and evidence-based medicine.

Authors:  Roberto Reverberi
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

3.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

Review 4.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

Review 5.  Clinical review: Fresh frozen plasma in massive bleedings - more questions than answers.

Authors:  Bartolomeu Nascimento; Jeannie Callum; Gordon Rubenfeld; Joao Baptista Rezende Neto; Yulia Lin; Sandro Rizoli
Journal:  Crit Care       Date:  2010-01-28       Impact factor: 9.097

6.  Virus-inactivated plasma - Plasmasafe: a one-year experience.

Authors:  Giustina De Silvestro; Paola Bagatella; Tiziana Tison; Vania Quaino; Paolo Carraro; Maria Luisa Tenderini; Annarosa Lazzaro; Alberto Marotti
Journal:  Blood Transfus       Date:  2007-07       Impact factor: 3.443

7.  Splenectomy and proximal lieno-renal shunt in a factor five deficient patient with extra-hepatic portal vein obstruction.

Authors:  Srinivas Prabhu Chava; Sujoy Pal; Supriyo Ghatak; Rajat Kumar; Peush Sahni; Tushar Kanti Chattopadhyay
Journal:  BMC Surg       Date:  2006-05-19       Impact factor: 2.102

8.  Solvent/detergent plasma: pharmaceutical characteristics and clinical experience.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.